Hopeful law firms in search of plaintiffs for kickback suits against Sanofi

Sanofi ($SNY) made its fair share of bad headlines in the latter half of 2014, and law firms are hoping that means one thing: plaintiffs for shareholder lawsuits against the French drugmaker. Potential claims focus on an alleged illegal kickback strategy for the company's diabetes franchise, designed to boost sales. More

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.